MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.160
-0.040
-3.34%
Closed 16:00 12/12 EST
OPEN
1.180
PREV CLOSE
1.200
HIGH
1.190
LOW
1.150
VOLUME
86.54K
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
0.6000
MARKET CAP
41.62M
P/E (TTM)
-2.3195
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VBLT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VBLT News

  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.12/06 03:03
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.12/05 20:32
  • Hedge fund titan Steve Cohen in talks to increase his stake in Mets
  • CNBC.com.12/04 20:44
  • Mayor Pete is Hollywood's top pick now that Kamala Harris is out of the presidential race
  • CNBC.com.12/04 13:15

More

Industry

Biotechnology & Medical Research
+0.57%
Pharmaceuticals & Medical Research
+0.73%

Hot Stocks

Name
Price
%Change

About VBLT

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
More

Webull offers Vascular Biogenics Ltd (VBLT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.